Assenagon Asset Management S.A. Has $909,000 Holdings in Syros Pharmaceuticals, Inc. (NASDAQ:SYRS)

Assenagon Asset Management S.A. grew its position in shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS - Free Report) by 576.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 169,999 shares of the company's stock after acquiring an additional 144,869 shares during the quarter. Assenagon Asset Management S.A. owned about 0.64% of Syros Pharmaceuticals worth $909,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently modified their holdings of the company. Opaleye Management Inc. bought a new stake in Syros Pharmaceuticals during the 4th quarter valued at $2,799,000. Flagship Pioneering Inc. increased its position in shares of Syros Pharmaceuticals by 30.2% during the fourth quarter. Flagship Pioneering Inc. now owns 1,293,848 shares of the company's stock worth $10,079,000 after acquiring an additional 300,000 shares in the last quarter. Avidity Partners Management LP raised its holdings in shares of Syros Pharmaceuticals by 5.8% in the 4th quarter. Avidity Partners Management LP now owns 1,673,538 shares of the company's stock worth $13,037,000 after acquiring an additional 92,396 shares during the last quarter. Bain Capital Life Sciences Investors LLC lifted its position in Syros Pharmaceuticals by 29.4% in the 4th quarter. Bain Capital Life Sciences Investors LLC now owns 2,749,808 shares of the company's stock valued at $21,421,000 after acquiring an additional 625,114 shares in the last quarter. Finally, CHI Advisors LLC boosted its stake in Syros Pharmaceuticals by 69.3% during the 3rd quarter. CHI Advisors LLC now owns 1,299,359 shares of the company's stock valued at $5,119,000 after purchasing an additional 531,914 shares during the last quarter. 91.47% of the stock is owned by institutional investors and hedge funds.

Syros Pharmaceuticals Stock Up 0.7 %

NASDAQ:SYRS traded up $0.04 on Tuesday, hitting $5.65. The stock had a trading volume of 68,587 shares, compared to its average volume of 195,665. Syros Pharmaceuticals, Inc. has a 1 year low of $2.09 and a 1 year high of $8.17. The firm's fifty day simple moving average is $5.43 and its two-hundred day simple moving average is $5.63. The company has a debt-to-equity ratio of 1.97, a quick ratio of 3.01 and a current ratio of 3.01. The stock has a market cap of $151.02 million, a P/E ratio of -1.11 and a beta of 1.75.

Syros Pharmaceuticals (NASDAQ:SYRS - Get Free Report) last issued its quarterly earnings results on Tuesday, May 14th. The company reported ($0.79) EPS for the quarter, topping analysts' consensus estimates of ($0.89) by $0.10. Syros Pharmaceuticals had a negative return on equity of 395.36% and a negative net margin of 1,656.34%. During the same quarter last year, the company earned ($0.85) EPS. Analysts predict that Syros Pharmaceuticals, Inc. will post -2.96 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently commented on SYRS shares. StockNews.com raised Syros Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Wednesday, May 15th. Piper Sandler reissued an "overweight" rating and issued a $13.00 price target on shares of Syros Pharmaceuticals in a research report on Wednesday, April 3rd. Finally, HC Wainwright reaffirmed a "buy" rating and set a $15.00 price objective on shares of Syros Pharmaceuticals in a report on Wednesday, May 15th.

Syros Pharmaceuticals Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.